# A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors

> **NCT01760525** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Solid Tumor With p53 Wild Type Status

## Interventions

- **DRUG:** CGM097

## Key facts

- **NCT ID:** NCT01760525
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-20
- **Primary completion:** 2020-07-24
- **Final completion:** 2020-07-24
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01760525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01760525, "A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01760525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*